A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase III
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Filgrastim; Paclitaxel; Pegfilgrastim
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-522
- Sponsors Merck Sharp & Dohme
- 09 Jul 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Nov 2018.
- 09 Jul 2018 Planned primary completion date changed from 1 Nov 2018 to 21 Sep 2018.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology